While S100A9, its binding partner S100A8 and its receptor TLR4 were all significantly upregulated in AML patient compared to normal bone marrow sample, we observed no prognostic value for these genes in AML patients (Fig. 1C–F, Supplemental Fig. 1). This evidence concerns the gene TLR4 and acute myeloid leukemia.